Table 1.

In vivo arachidonic acid therapeutic action.

Experimental host	Schistosome species			Ref
	Schistosoma mansoni a	Schistosoma haematobium b
Mice				(21)
ARA dose	1,000 mg/kg	1,000 mg/kg
Worm burden decrease	P = 0.007; 37.9%	P = 0.003; 57.7%
ARA dose	300 mg/kg/d c for 15 d	300 mg/kg/d for 15 d
Worm burden decrease	P = 0.001;63.6%	P = 0.007; 81.4%
Hamsters				(22)
ARA dose	300 + 2,500 mg/kg/d over 2 d	300 + 2,500 mg/kg/d over 2 d
Worm burden decrease	P = 0.017; 78.9%	P = 0.0002; 50.6%
Childrenc	Number of cured/total number of treated children (cure rate %)
	Light infection	Moderate infection	Heavy infection	Ref
Low endemicity region				(23)
PZQ 40 mg/kg once	12/14 (85)	5/6 (83)
ARA 10 mg/kg/d for 15 d	11/14 (78)	4/9 (44)
PZQ + ARA	14/16 (87)	7/7 (100)
High endemicity region				(24)
PZQ 40 mg/kg once	19/32 (60)	11/26 (42)	3/15 (20)
ARA 10 mg/kg/d for 15 d	12/24 (50)	3/23 (13)	3/14 (21%)
PZQ + ARA	19/23 (83)	13/23 (57)	11/14 (78)

^aMice and hamsters infected with S. mansoni were ARA-treated 6 weeks after infection.

^bMice and hamsters infected with S. haematobium were ARA-treated 12 weeks after infection.

^cChildren were infected with S. mansoni.

^dd = day.